Clinical Capabilities Throne Biotechnologies is a clinical-stage biotech with FDA-approved phase 2 INDs for Stem Cell Educator therapy targeting type 1 diabetes, alopecia areata and other autoimmune diseases, presenting a compelling entry point for collaboration with pharma and hospitals seeking innovative immune-modulating therapies.

Global Trials International multicenter clinical experience across Spain, China, and the US with over 200 patients demonstrates safety and efficacy, offering a track record to engage global health organizations, CROs, and translational partners for expanded trials or co-development deals.

Strategic Funding Recent capital raising activity via Regulation Crowdfunding signals interest in public capital channels; combined with revenue generation and modest funding, opportunities exist for strategic investors, grant-backed partnerships, and milestone-driven collaborations.

Technology Differentiator Proprietary cord blood-derived multipotent stem cell Educator therapy uniquely educates patient immune cells ex vivo before reinfusion, positioning Throne as a potential partner for large biopharma seeking differentiated immunotherapies with potential disease-modifying outcomes.

Market Alignment High unmet need in T1D and autoimmune diseases, compounded by post-COVID-19 vascular/immunological considerations, creates a favorable environment for strategic alliances with endocrinology, immunology, and rare-disease focused companies aiming to broaden therapeutic portfolios.